Papilocare Vaginal Gel 21 canulas of 5 ml

Product Information

Papilocare contiene una combinación única de ingredientes naturales y científicamente probados que trabajan en conjunto para abordar las lesiones causadas por el VPH y promover un entorno vaginal saludable. Algunos de los principales ingredientes de Papilocare incluyen: Use one application per day for the first 21 days. After 21 days, continue with one application every other day for 5 months. Approximately 30% of Spanish women younger than 30 years are HPV carriers. 25 The likelihood of HPV infection decreases over time, from 47% between the ages of 15 and 19 years to 12% in women older than 45 years. 26 The HPV is a fundamental factor for the development of cervical cancer. 27 The World Health Organization has recently established the elimination of cervical cancer as a priority medium-term objective. 28 This trial aimed to explore whether treatment with Papilocare provides better results than the conventional watchful waiting strategy in improving low-grade cervical lesions, which are the first step in the natural history of cervical cancer. 29 Clearance of LSILs after a conservative approach is of approximately 59% within 2 years of the diagnosis. Nevertheless, the likelihood of progression of these lesions to a high-grade squamous intraepithelial lesion within 5 years is 12.7%. 30 In addition, treatments for cervical cancer severely compromise the reproductive health of women. In a systematic review of Cochrane, Kyrgiou et al. 31 demonstrated a higher baseline risk for prematurity in women with cervical intraepithelial neoplasia, which increased with excisional and ablative treatments. Therefore, the scenario is conflicting, as choosing an excisional or ablative approach for the treatment of LSILs can result in negative reproductive outcomes, but avoiding treatment and just monitoring the disease results in its progression to high-grade lesions in 12 of 100 women. The current recommendation in Spain also includes monitoring the disease. 32, 33 However, based on the results of this present study, a novel strategy involving Papilocare has become available. The results of this treatment in the repair of low-grade lesions have demonstrated to significantly exceed those obtained with the watchful waiting approach (8 in 10 women achieved a normalization in their lesions). Antes de comenzar cualquier tratamiento, especialmente si está embarazada, en periodo de lactancia o tiene antecedentes de alergias o problemas médicos, siempre es recomendable consultar a un profesional de la salud para asegurarse de que el tratamiento sea adecuado y seguro para usted. Virus del Papiloma Humano Testimonios y experiencias de pacientes Historias de éxito en el uso de Papilocare Este posibil ca o cantitate mică de gel să rămână în aplicator. Aceasta nu înseamnă că doza a fost administrată

You can use Papilocare® at any time of day, but the gel is more likely to remain in place if you apply it just before bedtime. Crearea conditiilor pentru o vindecare rapida a leziunilor cauzate de scarpinat datorita senzatiei de arsurasi mancarimii. MAMA SI COPILUL: SCUTECE SI SERVETELE ALIMENTATIE COPII IGIENA SI INGRIJIRE COPII AFECTIUNI SI BOLI SPECIFICE MATERNITATE Papilocare je dostupan kao jednodozni aplikator za primjenu u rodnicu. Sve aplikatore koji su otvoreni ili oštećeni treba baciti. Aplikator je dizajniran za lakšu primjenu proizvoda.Crearea conditiilor pentru o vindecare rapida a leziunilor cauzate de scarpinat datorita senzatiei de arsura si mancarimii. membrana mucoasă a colului uterin și a vaginului (3 ml). După utilizare, aplicatorul trebuie aruncat. Aplicator

Papilocare je gel koji djeluje tako što stvara sloj na sluznici vrata maternice, oblikujući obrambenu barijeru za sprječavanje rizika od integracije HPV-a. Na taj način se prekida integracija HPV-a i stvaranje novih lezija te pomaže ponovnu epitelizaciju postojećih lezija. The percentage of patients with normal Pap smear and concordant colposcopy 3 and 6 months after receiving treatment (78.0% and 84.9%) was significantly higher than without treatment (54.8% and 64.5%), especially in high-risk HPV patients (79.5% and 87.8% vs 52.0% and 56.0%). At 6-month visit, overall HPV clearance was achieved by a greater number of patients receiving treatment (59.6%) compared with those without treatment (41.9%), especially high-risk HPV ones (62.5% vs 40.0%). The cervical re-epithelization score was significantly higher with treatment (mean = 4.5) than without (mean = 4.1). Compared with baseline, perceived stress decreased in the treatment group (from 21.1 to 19.0) and increased in the control group (from 17.7 to 20.7). A total of 7 possible or probable treatment-related adverse events were reported, most of them (n = 6) being mild or moderate in severity. Conclusions Compared with the baseline, the percentual change in the vaginal health index after 3 and 6 months of follow-up was numerically higher in the treatment group (mean percentual change of 2.5% [SD = 13.1] at the 3-month visit and of 3.7% [SD = 15.2] at the 6-month visit) compared with the control group (−0.1% [SD = 10.8], p = .249 and −1.3% [SD = 12.3], p = .067, respectively). A trend toward an improvement in the vaginal health from baseline was observed in the treatment group (41.4% and 42.3% of women achieved an improvement at the 3- and 6-month visit, respectively) in comparison with the control group (31.3% and 29.0%, respectively). Perceived Stress sarcină, înainte de a utiliza Papilocare, este necesar să consultați un medic, iar aplicarea ar trebuiA differential but nonsignificant trend in this parameter was observed between both groups, in such a way that it decreased in the treatment group (from a mean of 21.1 [SD = 8.8] at baseline, to a mean of 19.7 [SD = 9.0] at 3 months, and, finally, a mean of 19.0 [SD = 9.1] at 6 months) and increased in the control group (from a mean of 17.7 [SD = 7.2] at baseline, to a mean of 17.4 [SD = 6.3], and, finally, a mean of 20.7 [SD = 9.8] at 3 and 6 months, respectively). The number of patients reporting an improvement in perceived stress was higher at the 3-month (35 of 56 women [62.5%]) and 6-month visits (29 of 50 women [58.0%]) in the treatment group compared with the control group (15 of 31 women [48.4%] and 11 of 28 women [39.3%], respectively). Satisfaction With the Product and Therapeutic Adherence

Extract de Neem: actiune emolienta care favorizeaza procesul natural de vindecare cu ameliorarea simptomelor de roseata si mancarime. Avertizări: Papilocare® nu trebuie utilizat de persoanele cu hipersensibilitate cunoscută la oricare dintre Không có dữ liệu khi dùng chung với những biện pháp tránh thai như vòng âm đạo. Vì vậy không nên dùng sản phẩm cho những người đang dùng biện pháp trên.

Medicamente din aceeasi categorie

după aplicare, cu o frecvență care nu depășește 1 din 10 de cazuri. Această reacție este mai frecventă Repair of HPV-dependent cervical lesions after 3 and 6 months of treatment in the total and HR HPV patient pools. *Normalized cytology together with concordant colposcopic observations. **χ 2 test. One high-risk HPV patient of the control group had missing data. Overall HPV Clearance sản xuất trên dây truyền công nghệ hiện đại chuẩn châu âu cho tác động nhắm trúng đích, tăng cường sinh khả dụng của sản phẩm.